TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Apr 12, 2021 13:16 JST
Source:
Eisai
Eisai: Animation Featuring Lymphatic Filariasis Elimination Activities Receives Animation Award at International Society for Neglected Tropical Diseases Festival 2021
TOKYO, Apr 12, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced that its animation "Leave No One Behind-Disease of Neglected People" which features activities for the elimination of lymphatic filariasis (LF) has received the Animation Award at the International Society for Neglected Tropical Diseases (ISNTD) Festival 2021.
ISNTD Festival is an annual event aiming to increase awareness about neglected tropical diseases (NTDs) and this year marks the 5th ISNTD Festival. At the ISNTD Festival Awards, which accompanies this festival, outstanding projects will be selected and awarded in each of the seven categories of animation, app, art, awareness campaign, mass media, photo, and video, related to NTDs.
The award-winning animation "Leave No One Behind" features the 10-year LF elimination activities of Eisai and its global partners which have been implemented since Eisai signed a joint statement with the World Health Organization (WHO) for the LF elimination in 2010. The animation highlights the feelings, thoughts and sufferings of patients which were perceived through activities for free provision of medicines and disease awareness. In addition, the animation highlights tremendous efforts of global partners including Eisai dedicated for drug delivery to remote regions, disease awareness activities for residents in endemic regions and support for mass drug administrations (MDAs), in order to make necessary medicines available to those who need them.
Eisai has been manufacturing diethylcarbamazine (DEC tablets), one of the LF treatments, at its Vizag Plant in India and has been providing to LF endemic countries for free since 2013. We have provided 2.01 billion DEC tablets to 28 countries and contributed to LF elimination in Egypt, Kiribati, Thailand and Sri Lanka. We have also been collaborating with global partners on disease awareness for LF and support for implementation of MDAs necessary for the LF elimination. Eisai announced to continue providing DEC tablets for free to endemic countries that need DEC until LF is eliminated in these countries.
By accelerating the development of new medicines for infectious diseases and NTDs including LF which are endemic in developing and emerging countries via leveraging partnerships, together with implementing activities to improve access to medicines including raising disease awareness locally and implementing price setting models that take income levels into account, Eisai strives to further contribute to increasing the benefits for patients and their families worldwide.
Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
March 02 2026 08:49 JST
Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy
February 16 2026 13:03 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Designated for Priority Review in China
February 10 2026 12:34 JST
Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
February 06 2026 10:31 JST
FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
January 26 2026 10:37 JST
Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time
January 21 2026 15:44 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
January 13 2026 08:50 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
January 06 2026 09:43 JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
December 11 2025 18:41 JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
December 09 2025 17:51 JST
More Press release >>
Latest Press Release
Fujitsu and DT-Axis collaborate to advance digital health
Mar 09, 2026 13:32 JST
Hong Kong Completes First Green Methanol Bunkering, Driving Green Transformation of Its International Shipping Hub
Mar 08, 2026 16:05 JST
International Women's Day: Why Menopause May Be a Missed Cardiovascular Risk Window
Mar 06, 2026 20:00 JST
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 05, 2026 22:00 JST
Honda to Begin Sales of Two U.S.-built Vehicles in Japan
Mar 05, 2026 16:47 JST
DOCOMO's New Haptic-sharing System Enables Fans to Feel Closer to Idols
Mar 05, 2026 16:38 JST
TANAKA Establishes Transfer Technology for its Sintered Gold (Au) Bonding Technology, AuRoFUSE(TM) Preforms
Mar 03, 2026 22:00 JST
Fujitsu and BCN Port Innovation Foundation leverage ocean digital twin technology to drive the regeneration of the Port of Barcelona
Mar 03, 2026 21:00 JST
MHI and SoftBank Corp. Collaborate to Adapt AI-RAN Network Architecture for Edge Data Centers
Mar 02, 2026 19:13 JST
DOCOMO and NEC Launch Japan's First Commercial 5G Core on AWS, Built with World's First AI-automated Network Construction Technology
Mar 02, 2026 16:34 JST
Fujitsu supports sustainable growth for retailers with data and AI through Uvance for Retail
Mar 02, 2026 11:55 JST
WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Mar 02, 2026 09:49 JST
NEC Strengthens Multi-Vendor Optical Network Solutions with New TIP-Certified Phoenix Hardware Lineup
Feb 27, 2026 18:50 JST
NEC Demonstrates Agentic AI-Driven Autonomous Network Operations in Collaboration with AWS
Feb 27, 2026 17:31 JST
Mitsubishi Heavy Industries Compressor Acquires Swiss Rotating Equipment Maintenance Company AST Turbo AG
Feb 27, 2026 17:23 JST
NEC Strengthens Its Edge Portfolio for the 6G Era, Enabling Efficient Edge Deployment and Integration with Cloud Services
Feb 27, 2026 12:24 JST
Fujitsu POS solution enhances customer experience at Hankyu Hanshin Department Stores
Feb 27, 2026 12:03 JST
Mitomo Semicon Engineering to Change Company Name
Feb 26, 2026 22:00 JST
The University of Tokyo, NTT, and NEC demonstrate real-time augmented reality assistance made possible by integrating three newly proposed technologies on a 6G/IOWN platform to realize the widespread use of AI agents supporting safety and security
Feb 26, 2026 19:01 JST
NEC and Nokia to Expand Eletronet's Optical Fiber Network in Brazil by 50%
Feb 26, 2026 18:51 JST
More Latest Release >>